ResMed
Logotype for ResMed Inc

ResMed (RMD) investor relations material

ResMed Q1 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ResMed Inc
Q1 2027 earnings summary29 Oct, 2026

Executive summary

  • Q1 FY27 revenue was $1,414.8M, up 6% reported and 7% core constant currency; non-GAAP diluted EPS rose 14% to $2.91.

  • Sleep-portfolio demand and higher gross margin supported growth; MatrixCare proceeds and cash generation funded more than $1.0B in shareholder returns.

Financial highlights

  • GAAP net income was $418.4M versus $348.5M; GAAP diluted EPS was $2.92 versus $2.37.

  • Non-GAAP gross margin was 62.5%, up 50 bps; non-GAAP operating margin was 35.8%, down 30 bps, and non-GAAP net income was $418M versus $375M.

  • Operating cash flow was $422M and free cash flow was $374M, down 8% and 10% YoY, respectively.

  • MatrixCare's sale contributed a preliminary $62M pretax gain; GAAP operating income was $453.0M versus $446.5M.

Outlook and guidance

  • FY27 guidance remained unchanged: core constant-currency revenue growth of 5%-7%, reported revenue of $5.75B-$5.85B, and non-GAAP diluted EPS of $12.00-$12.25.

  • Revenue guidance includes an ~130 bps or $75M Astral impact and ~60 bps of FX pressure; excluding Astral, core constant-currency growth would be 6.3%-8.3%.

  • FY27 gross margin is expected to expand by low-double-digit bps, with a slight increase in operating margin; quarterly variability is expected.

  • FY27 capital returns are expected to exceed $1.85B; capex guidance is $160M-$180M. Q2 revenue is expected to follow typical mid-single-digit sequential seasonality.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next ResMed earnings date

Logotype for ResMed Inc
AGM 202618 Nov, 2026
ResMed
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next ResMed earnings date

Logotype for ResMed Inc
AGM 202618 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ResMed Inc. develops, manufactures, and markets medical devices, including equipment for the diagnosis and treatment of obstructive sleep apnea (OSA), related breathing disorders and other medical conditions connected to respiration. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.